Health Care [ 4/12 ] | Biotechnology [ 18/73 ]
NASDAQ | Common Stock
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease.
The company was founded in 2018 and is based in New York, New York.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 25 | -0.73 Increased by +1.35% | -0.71 Decreased by -2.82% |
| Aug 11, 25 | -0.71 Decreased by -18.33% | -0.70 Decreased by -1.43% |
| May 29, 25 | -0.64 Decreased by -23.08% | -0.71 Increased by +10.11% |
| Feb 10, 25 | -0.76 Decreased by -111.11% | -0.75 Decreased by -1.02% |
| Nov 7, 24 | -0.74 Decreased by -64.44% | -0.60 Decreased by -23.33% |
| Aug 6, 24 | -0.60 Decreased by -5.26% | -0.53 Decreased by -13.21% |
| May 29, 24 | -0.52 Decreased by -13.04% | -0.43 Decreased by -20.93% |
| Feb 12, 24 | -0.36 Increased by +26.53% | -0.43 Increased by +16.28% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 0.00 Decreased by N/A% | -126.50 M Decreased by -15.93% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -120.61 M Decreased by -38.40% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 160.00 K Decreased by -89.33% | -106.45 M Decreased by -41.33% | Decreased by -66.53 K% Decreased by -1.22 K% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -111.12 M Decreased by -116.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -109.12 M Decreased by -86.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -87.15 M Decreased by -17.87% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 1.50 M Increased by +N/A% | -75.32 M Decreased by -26.73% | Decreased by -5.02 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -51.42 M Increased by +18.68% | Decreased by N/A% Decreased by N/A% |